Analysts at Motilal Oswal Wealth Management Research Desk are bullish on mid-caps Indian Hotels and Lenskart, and small-caps Symbiotec Pharmalab and Urban Company.
Q1 FY27 has surprised positively at the aggregate level: ex-OMCs, corporate earnings grew around 17 per cent YoY, led by BFSI, metals, technology and autos, said Vinit Bolinjkar.
From a broader perspective, we continue to see value in areas like software where valuations remain reasonable relative to long-term growth potential, says Rajat Chandak.
The medium-term outlook for the banking sector remains constructive, supported by healthy credit growth, stable asset quality and improving liquidity conditions, says Motilal Oswal.
Indian markets have rebounded in April, with Nifty50 rising nearly 3 per cent this month. Analysts, however, say sentiment remains cautious. Here's why it's not yet a broad-based buy-on-dips phase
Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.
Geopolitical tensions, rising crude prices, and sustained FII outflows are reshaping the outlook for Indian equities. Mythili Balakrishnan shares views on market direction and investment strategy
After a volatile FY26, markets are entering FY27 with uncertainty, but also opportunity. From equities and gold to bonds and real estate, here’s what top analysts are saying about where to invest,
As markets navigate geopolitical uncertainty, investors are recalibrating their strategies. Harshad Patil, CIO at Tata AIA Life, outlines how he is positioning portfolios amid the Iran conflict
Retail investors remain resilient amid Iran war volatility, shifting towards index investing, diversification, and long-term strategies, says smallcase CEO.
Emkay Global warns of a 10-per cent downside in Nifty as Iran war volatility keeps crude oil above $100 per barrel. It has picked HDFC Bank, Eternal, and Max Healthcare as top stocks to buy now.
Global headwinds dragged the Sensex and Nifty indices nearly 8 per cent from record high levels in 2026. Analysts think worst is over; suggest staggered buying in banking, auto, defence and pharma
